Didierlaurent Arnaud, Ramirez Juan-Carlos, Gherardi Magdalena, Zimmerli Simone C, Graf Marcus, Orbea Hans-Acha, Pantaleo Giuseppe, Wagner Ralf, Esteban Mariano, Kraehenbuhl Jean-Pierre, Sirard Jean-Claude
Swiss Institute for Experimental Cancer Research (ISREC), Institute of Biochemistry, University of Lausanne, CH-1066 Epalinges, Switzerland.
Vaccine. 2004 Sep 3;22(25-26):3395-403. doi: 10.1016/j.vaccine.2004.02.025.
Efficient HIV vaccines have to trigger cell-mediated immunity directed against various viral antigens. However little is known about the breadth of the response induced by vaccines carrying multiple proteins. Here, we report on the immunogenicity of a construct harbouring a fusion of the HIV-1 IIIB gag, pol and nef genes (gpn) designed for optimal safety and equimolar expression of the HIV proteins. The attenuated poxviruses, MVA and NYVAC, harbouring the gpn construct, induced potent immune responses in conventional mice characterised by stimulation of Gpn-specific IFN-gamma-producing cells and cytotoxic T cells. In HLA-A2 transgenic mice, recombinant MVA elicited cytotoxic responses against epitopes recognised in most HLA-A2+ HIV-1-infected individuals. We also found that the MVA vaccine triggered the in vitro expansion of peripheral blood cells isolated from a HIV-1-seropositive patient and with similar specificity as found in immunised HLA-A2 transgenic mice. In conclusion, the synthetic HIV polyantigen Gpn delivered by MVA is immunogenic, efficiently processed and presented by human MHC class I molecules.
高效的HIV疫苗必须引发针对多种病毒抗原的细胞介导免疫。然而,对于携带多种蛋白质的疫苗所诱导的免疫反应广度了解甚少。在此,我们报告一种构建体的免疫原性,该构建体包含HIV-1 IIIB型gag、pol和nef基因(gpn)的融合体,其设计目的是实现最佳安全性以及HIV蛋白的等摩尔表达。携带gpn构建体的减毒痘病毒MVA和NYVAC在常规小鼠中诱导了强烈的免疫反应,其特征为刺激产生Gpn特异性干扰素-γ的细胞和细胞毒性T细胞。在HLA-A2转基因小鼠中,重组MVA引发了针对大多数HLA-A2 + HIV-1感染个体中所识别表位的细胞毒性反应。我们还发现,MVA疫苗触发了从一名HIV-1血清阳性患者分离的外周血细胞在体外的扩增,且具有与免疫的HLA-A2转基因小鼠中发现的相似特异性。总之,由MVA递送的合成HIV多抗原Gpn具有免疫原性,能被人MHC I类分子有效加工和呈递。